Muscle relaxation in kidney insufficiency and antagonism
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
I now have comprehensive information from the textbooks. Let me compile the full answer.
Muscle Relaxation in Renal Insufficiency and Antagonism
Overview
The kidney plays a major role in the elimination of many neuromuscular blocking drugs (NMBDs) and their reversal agents. Renal insufficiency can significantly alter the pharmacokinetics of both categories - understanding which drugs are safe, which are prolonged, and how to reverse them appropriately is essential for anesthetic practice.
1. Depolarizing Relaxants in Renal Failure
Succinylcholine
- Metabolized by plasma cholinesterases (pseudocholinesterase); renal elimination is minimal for the parent compound
- Plasma cholinesterase activity is moderately reduced (~30%) in renal failure, but this does not clinically prolong succinylcholine blockade
- Key concern: Succinylcholine causes a transient rise in plasma K+ of ~0.5 mmol/L. This is generally tolerated in patients with chronically elevated potassium, but avoid it if serum K+ is dangerously elevated
- Its metabolite succinylmonocholine (weakly active) is renally excreted - continuous infusions are therefore cautioned
- Conclusion: Single-dose succinylcholine is acceptable in renal failure for rapid-sequence induction, provided K+ is not critically elevated
2. Nondepolarizing Relaxants in Renal Failure
Long-Acting Agents (Avoid in Renal Failure)
| Drug | Renal Excretion | Effect in Renal Failure |
|---|---|---|
| Pancuronium | ~60-80% | Half-life increased ~500% in severe renal failure; markedly prolonged blockade |
| d-Tubocurarine | ~60% | Reduced clearance, prolonged duration |
| Doxacurium | High | Increased elimination half-life, reduced clearance, prolonged effect |
| Pipecuronium | High | Similar pharmacokinetic changes to doxacurium |
Long-acting NMBDs should not be used in patients with renal failure due to unpredictably prolonged blockade and the availability of safer alternatives. - Miller's Anesthesia, 10e
Intermediate-Acting Agents
| Drug | Renal Excretion | Effect in Renal Failure | Notes |
|---|---|---|---|
| Vecuronium | ~15-25% | Clearance reduced; elimination half-life increased | Active metabolite 3-desacetylvecuronium (80% potency of parent) accumulates - can cause prolonged paralysis especially in ICU patients |
| Rocuronium | ~10-25% | Duration not significantly prolonged at standard doses | Primarily biliary excretion (>75%); relatively safer in renal dysfunction |
| Atracurium | Minimal | Duration unaffected by renal failure | Undergoes Hofmann elimination + ester hydrolysis (50% of clearance); metabolite laudanosine renally excreted but seizure threshold not reached clinically |
| Cisatracurium | ~16% | Not prolonged in renal failure | Hofmann elimination accounts for 77% of clearance; 10x lower laudanosine levels than atracurium; preferred agent in renal failure |
Atracurium and cisatracurium are the preferred muscle relaxants in renal (and hepatic) insufficiency because their elimination via Hofmann elimination and ester hydrolysis is independent of kidney function. - Barash, 9e; Morgan & Mikhail, 7e
Mivacurium
- Primarily metabolized by plasma cholinesterase; minimal renal excretion of parent compound
- Duration not significantly affected by renal dysfunction, though reduced pseudocholinesterase in severe renal failure could slow metabolism modestly
3. Reversal Agents in Renal Failure
Cholinesterase Inhibitors (Neostigmine, Edrophonium, Pyridostigmine)
- Clearance via hepatic metabolism (25-50%) and renal excretion (50-75%)
- In renal failure, their elimination is delayed - paralleling the prolonged duration of the NMBDs they are reversing
- Key principle: Any prolongation of a nondepolarizing NMBD from renal or hepatic insufficiency will probably be accompanied by a corresponding increase in the duration of the cholinesterase inhibitor - Morgan & Mikhail, 7e, p.417
- This "matched prolongation" is actually clinically advantageous - the reversal agent lasts as long as the NMBD
- Must still give anticholinergic (atropine or glycopyrrolate) to counteract muscarinic side effects (bradycardia, bronchospasm, hypersalivation)
Sugammadex in Renal Failure
Sugammadex is a modified gamma-cyclodextrin that encapsulates steroidal NMBDs (rocuronium, vecuronium, pancuronium) in a 1:1 ratio, rapidly reversing blockade.
Pharmacokinetics:
- Eliminated unchanged in urine as the sugammadex-NMBD complex
- In normal renal function (CrCl >80 mL/min): complex excreted in urine within 24 hours; elimination half-life ~100 minutes
- In mild-moderate renal insufficiency (CrCl 30-80 mL/min): half-life extends to 4-6 hours - sugammadex can still be used safely
- In severe renal impairment (CrCl <30 mL/min): half-life extends to ~19 hours; both sugammadex and the sugammadex-rocuronium complex accumulate significantly
Clinical Evidence in Renal Failure:
- Sugammadex 2 mg/kg in severe renal impairment (CrCl <30 mL/min) achieved reversal comparably to normal renal function patients, with no difference in residual block incidence
- Deep block reversal (4 mg/kg) took 3.1 min (vs. 1.9 min in controls) - still clinically acceptable
- A cohort of 219 patients with GFR <15 mL/min tolerated sugammadex well
- Hemodialysis (high-flux method) can remove sugammadex and the rocuronium-sugammadex complex in severe renal impairment
- Rocuronium + sugammadex used successfully in renal transplantation patients
Current Recommendations:
- Sugammadex is acceptable and effective in mild to moderate renal dysfunction (CrCl 30-80 mL/min)
- In severe renal failure (CrCl <30 mL/min): sugammadex is not routinely recommended because elimination of the complex is poorly understood and accumulation may occur. However it may be used when absolutely necessary, and high-flux hemodialysis can remove the complex if needed
- Sugammadex is not recommended in end-stage renal disease unless necessary - Katzung's, 16e; Miller's Anesthesia, 10e; Barash, 9e
4. Summary Table: Preferred Agents
| Category | Preferred in Renal Failure | Avoid/Use with Caution |
|---|---|---|
| Depolarizing | Succinylcholine (single dose, if K+ safe) | Succinylcholine infusion |
| Nondepolarizing | Cisatracurium > Atracurium | Pancuronium, d-tubocurarine, vecuronium (high doses/ICU) |
| Reversal | Neostigmine (matched prolongation) | Sugammadex (use cautiously if CrCl <30) |
5. Additional Considerations in Renal Failure
- Electrolyte disturbances (hypokalemia, hypocalcemia, hypermagnesemia) potentiate nondepolarizing blockade
- Respiratory acidosis potentiates blockade and antagonizes reversal - must ensure adequate ventilation before attempting reversal
- Drug interactions - aminoglycosides, diuretics, immunosuppressants, and magnesium-containing antacids may alter NMBD pharmacodynamics
- Quantitative neuromuscular monitoring (acceleromyography, TOF monitoring) is strongly recommended in renal failure patients to guide dosing and confirm complete reversal before extubation
Sources:
- [Morgan & Mikhail's Clinical Anesthesiology, 7e](p. 392, 410, 417)
- [Miller's Anesthesia, 10e](pp. 3325-3327, 3437)
- [Barash's Clinical Anesthesia, 9e](pp. 4265-4266)
- [Katzung's Basic and Clinical Pharmacology, 16e](p. 759)
This is a shared conversation. Sign in to Orris to start your own chat.